<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02395640</url>
  </required_header>
  <id_info>
    <org_study_id>FDZL-EXELOX</org_study_id>
    <nct_id>NCT02395640</nct_id>
  </id_info>
  <brief_title>The Comparison of XELOX and EOX in the First-line Treatment of Advanced Gastric Cancer</brief_title>
  <official_title>The Comparison of XELOX and EOX in the First-line Treatment of Advanced Gastric Cancer: An Open-label, Multi-center, Prospective and Randomised Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fudan University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Fudan University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is designed to compare the efficacy and safety of XELOX regimen with EOX regimen&#xD;
      in the first-line treatment of advanced gastric cancer patients.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study is designed to compare the efficacy and safety of XELOX regimen with EOX regimen&#xD;
      in the first-line treatment of advanced gastric cancer patients.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>March 2015</start_date>
  <completion_date type="Actual">February 23, 2021</completion_date>
  <primary_completion_date type="Actual">February 23, 2021</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>progression free survival</measure>
    <time_frame>7 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>overall survival</measure>
    <time_frame>10 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>overall response rate</measure>
    <time_frame>2 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants with Adverse Events</measure>
    <time_frame>2 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>quality of life questionnaire</measure>
    <time_frame>2 months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">438</enrollment>
  <condition>Gastric Cancer</condition>
  <arm_group>
    <arm_group_label>XELOX</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>oxaliplatin 130mg/m2 d1； capecitabine 1000mg/m2 Bid po，d1-14；</description>
  </arm_group>
  <arm_group>
    <arm_group_label>EOX</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Epirubicin 50mg/m2 d1； oxaliplatin 130mg/m2 d1； capecitabine 1000mg/m2 Bid po，d1-14；</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Epirubicin</intervention_name>
    <description>50mg/m2 ivgtt d1</description>
    <arm_group_label>EOX</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Oxaliplatin</intervention_name>
    <arm_group_label>EOX</arm_group_label>
    <arm_group_label>XELOX</arm_group_label>
    <other_name>130mg/m2 ivgtt d1</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Capecitabine</intervention_name>
    <description>1000mg/m2 po d1-14</description>
    <arm_group_label>EOX</arm_group_label>
    <arm_group_label>XELOX</arm_group_label>
    <other_name>Xeloda</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Major inclusion criteria&#xD;
&#xD;
          -  had a histologically proven adenocarcinoma of the gastroesophageal junction, or&#xD;
             stomach that was locally advanced (inoperable) or metastatic&#xD;
&#xD;
          -  measurable disease, according to the Response Evaluation Criteria in Solid Tumors&#xD;
             (RECIST)1.1&#xD;
&#xD;
          -  an Eastern Cooperative Oncology Group performance status of 0 to 2&#xD;
&#xD;
          -  adequate renal, hepatic, and hematologic function&#xD;
&#xD;
        Major exclusion criteria&#xD;
&#xD;
          -  previous chemotherapy or radiotherapy (unless in the adjuvant setting)&#xD;
&#xD;
          -  uncontrolled cardiac disease, or other clinically significant, uncontrolled coexisting&#xD;
             illness or previous or concurrent cancer&#xD;
&#xD;
          -  accumulated dose of Epirubicin exceeds 300mg/m2&#xD;
&#xD;
          -  HER2 positive and willing to use trastuzumab&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Fudan University Cancer Hospital</name>
      <address>
        <city>ShangHai</city>
        <state>Shanghai</state>
        <zip>200032</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>March 2015</verification_date>
  <study_first_submitted>March 10, 2015</study_first_submitted>
  <study_first_submitted_qc>March 17, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 23, 2015</study_first_posted>
  <last_update_submitted>October 18, 2021</last_update_submitted>
  <last_update_submitted_qc>October 18, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 26, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Fudan University</investigator_affiliation>
    <investigator_full_name>Weijian Guo</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Stomach Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Capecitabine</mesh_term>
    <mesh_term>Oxaliplatin</mesh_term>
    <mesh_term>Epirubicin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

